La chaîne d'options affiche les données clés des options sur actions de PTC Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour PTC Therapeutics..

PTC Therapeutics (NASDAQ:PTCT) Stock, Chaîne d'Options

PTC THERAPEUTICS INC

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Inc

The&nbsp;European Commission (EC) adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)&nbsp;not to renew the authorization of PTC Therapeutics, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) Translarna (ataluren) for nonsense <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">mutation Duchenne muscular dystrophy (nmDMD)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44419721/ptc-therapeutics-reveals-new-sepiapterin-data-from-phase-3-study-in-patients-with-inherited-disorder-fda-decision-expected-in-july" rel="noreferrer noopener">PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July</a>
While this action effectively removes the drug's conditional marketing authorization in the European Economic Area, the EC indicated that individual countries within the European Union could leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44535458/ptc-therapeutics-provides-regulatory-update-on-translarna-ataluren-in-europe" rel="noreferrer noopener">continued use of Translarna</a>.
"We are of course disappointed that after this prolonged period of review the European Commission has decided to adopt the CHMP negative opinion on Translarna," said&nbsp;Matthew B. Klein, PTC Therapeutics CEO in a statement on Friday.
"We look forward to working on a country-by-country basis to provide commercial drug where possible."
In May 2024, PTC Therapeutics announced that the European Commission (EC) has decided not to adopt the CHMP's negative opinion on the annual renewal of Translarna's conditional marketing authorization (ataluren) and has returned the opinion to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38922172/european-commission-requests-reevaluation-of-opinion-on-ptc-therapeutics-duchenne-dystrophy-drug-" rel="noreferrer noopener">CHMP for re-evaluation</a>.&nbsp;
Translarna's net product revenues were&nbsp;$339.9 million&nbsp;for the full year 2024, compared to&nbsp;$355.8 million&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44024275/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial" rel="noreferrer noopener">for the full year 2023</a>.
In 2024, PTC submitted four regulatory approval applications to the FDA, all of which have been accepted for review, including Translarna for nmDMD.
Price Action: PTCT stock is down 1.76% at $54.02&nbsp;at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44522789/japan-approves-bridgebio-pharma-astrazeneca-partnered-rare-heart-disease-drug" target="_blank" rel="noreferrer noopener">Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug</a></li>
</ul>

Biotech

News

Health Care

General

PTCT

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder

On Thursday, PTC Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Annual Clinical Genetics Meeting</a>.
These data provide further evidence of the potential benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42272846/ptc-therapeutics-inks-licensing-pact-with-novartis-worth-3-billion-for-huntingtons-program" rel="noreferrer noopener">PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington&#8217;s Program</a>
Phenylketonuria is an inherited disorder that increases the levels of a substance called <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44414358/ptc-therapeutics-presents-new-sepiapterin-data-from-ongoing-studies" rel="noreferrer noopener">phenylalanine in the blood</a>.
Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures.
&#8220;These new data provide further evidence of the meaningful benefit sepiapterin can provide for children and adults with PKU, including those with the most severe form of the disease,&#8221; said Matthew Klein, CEO of PTC Therapeutics. &#8220;Furthermore, the treatment benefit demonstrated in individuals with mutations not responsive to BH4 and consistent with classical disease phenotype support the potential to penetrate all key patient segments.&#8221;
Treatment includes a strict diet with limited protein.
Key data presented include:
<ul>
<li>Over 97% of subjects participating in the Phe tolerance protocol of the APHENITY open-label extension study demonstrate the ability to liberalize their diet while on sepiapterin treatment, with a mean increase in protein intake of 126%.</li>
<li>66% of subjects participating in the Phe tolerance sub study reached or exceeded the age-adjusted recommended daily allowance of protein intake for an individual without PKU, while maintaining control of blood Phe levels.</li>
<li>Genetic variant analysis of subjects participating in the APHENITY study demonstrates that over 70% had a Genotype-Phenotype Value (GPV) consistent with classical PKU.</li>
</ul>
PTC submitted FDA regulatory approval applications in 2024 for sepiapterin for children and adults with PKU, with a target regulatory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44024275/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial" rel="noreferrer noopener">action date of&nbsp;July 29, 2025</a>.
PTC also submitted several additional marketing authorization applications outside the U.S. for sepiapterin in 2024. The CHMP opinion on sepiapterin MAA is expected in the second quarter of 2025. A regulatory decision in Japan is expected in the fourth quarter of 2025.
Price Action: PTCT stock is down 0.18% at $56.88 on Thursday&#8217;s last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/03/44415887/veon-reports-4-7-q4-sales-growth-as-digital-push-accelerates-eyes-double-digit-gains-in-2025" target="_blank" rel="noreferrer noopener">VEON Reports 4.7% Q4 Sales Growth As Digital Push Accelerates, Eyes Double-Digit Gains In 2025</a></li>
</ul>
Photo: Shutterstock

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July

—&nbsp;Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% —
— Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes —
WARREN, N.J., March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients, including significant diet liberalization.
Key data presented include:
<ul>
<li>Over 97% of subjects participating in the Phe tolerance protocol of the APHENITY open-label extension study demonstrate the ability to liberalize their diet while on sepiapterin treatment, with a mean increase in protein intake of 126%</li>
<li>66% of subjects participating in the Phe tolerance sub study reached or exceeded the age-adjusted recommended daily allowance of protein intake for an individual without PKU, while maintaining control of blood Phe levels</li>
<li>Genetic variant analysis of subjects participating in the APHENITY study demonstrates that over 70% had a Genotype-Phenotype Value (GPV) consistent with classical PKU</li>
</ul>

PTC Therapeutics Announces Phase 3 APHENITY Trial Results: Over 97% Of Subjects Participating In The Phe Tolerance Protocol Of The APHENITY Open-Label Extension Study Demonstrate The Ability To Liberalize Their Diet While On Sepiapterin Treatment, With A Mean Increase In Protein Intake Of 126%

JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $72 to $78.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on PTC Therapeutics, Raises Price Target to $78

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst David George upgraded the rating for Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) from Neutral to Outperform and raised the price target from $190 to $200. Capital One Finl shares closed at $163.87 on Monday. <a href="https://www.benzinga.com/quote/COF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Underperform to Neutral and raised the price target from $41 to $55. PTC Therapeutics shares closed at $52.49 on Monday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst David Roman upgraded the rating for GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) from Neutral to Buy and boosted the price target from $85 to $100. GE HealthCare shares closed at $85.36 on Monday. <a href="https://www.benzinga.com/quote/GEHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Durgesh Chopra upgraded CenterPoint Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) from In-Line to Outperform and raised the price target from $36 to $37. CenterPoint Energy shares closed at $34.43 on Monday. <a href="https://www.benzinga.com/quote/CNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Peter Supino upgraded the rating for Madison Square Garden Entertainment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGE#NYSE">MSGE</a>) from Peer Perform to Outperform and announced a $46 price target. Madison Square Garden shares closed at $30.59 on Monday. <a href="https://www.benzinga.com/quote/MSGE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEHC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11081519/image-65-1024x600.png" alt="" class="wp-image-818604" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11081519/image-65-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11081519/image-65-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11081519/image-65-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11081519/image-65.png 1141w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Upgrades

Pre-Market Outlook

Trading Ideas

GEHC

MSGE

This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

B of A Securities analyst Tazeen Ahmad upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Underperform to Neutral and raises the price target from $41 to $55.

B of A Securities Upgrades PTC Therapeutics to Neutral, Raises Price Target to $55

Scotiabank analyst Louise Chen initiates coverage on PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Sector Perform rating and announces Price Target of $55.

Initiation

Scotiabank Initiates Coverage On PTC Therapeutics with Sector Perform Rating, Announces Price Target of $55

Morgan Stanley analyst Jeffrey Hung assumes PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight rating and raises Price Target to $70.

Morgan Stanley Assumes PTC Therapeutics at Overweight, Raises Price Target to $70

JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $74 to $72.

JP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $72

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.66) by 28.79 percent. This is a 254.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $213.00 million which missed the analyst consensus estimate of $232.44 million by 8.36 percent. This is a 30.63 percent decrease over sales of $307.06 million the same period last year.

Earnings

Earnings Misses

PTC Therapeutics Q4 2024 Adj EPS $(0.85) Misses $(0.66) Estimate, Sales $213.00M Miss $232.44M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

The FDA Has Accepted PTC Therapeutics' New Drug Application For Vatiquinone For Children And Adults Living With Friedreich's Ataxia, Under Priority Review And Assigned A Prescription Drug User Fee Act Target Action Date Of August 19

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and raises the price target from $60 to $63.

RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $63

Citigroup analyst David Lebowitz maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Sell and raises the price target from $32 to $45.

Citigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $45

WIIM

PTC Therapeutics shares are trading higher after Cantor Fitzgerald raised its price target on the stock from $76 to $113.

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $76 to $113.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $113

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $80 to $76.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76

PTC Therapeutics Submits NDA To FDA For Vatiquinone As Potential First Approved Therapy For Friedreich Ataxia In Children And Adults, Marking Fourth FDA Application In 2024

Morgan Stanley analyst Jeffrey Hung upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Equal-Weight to Overweight and raises the price target from $45 to $67.

Morgan Stanley Upgrades PTC Therapeutics to Overweight, Raises Price Target to $67

On Friday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) revealed topline results from the APPULSE-PNH Phase 3B study of Fabhalta&nbsp;(iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab).
Ultomiris (ravulizumab) and Soliris&nbsp;(eculizumab) are commonly used anti-C5 therapies, and they are made by AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic stem cells, which are located in the bone marrow and can grow and develop into red blood cells, white blood cells, and platelets.
This mutation <a target="_blank" href="https://www.novartis.com/news/media-releases/new-phase-iiib-data-shows-novartis-fabhalta-improved-hemoglobin-levels-adult-patients-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-c5-therapy" rel="noreferrer noopener">causes</a> them to produce RBCs that are susceptible to premature destruction by the complement system.
After 24 weeks of treatment with Fabhalta, the average hemoglobin (Hb) level improved compared to baseline. The study&#8217;s safety profile of Fabhalta monotherapy was consistent with previously reported data.
Data will be presented at an upcoming medical meeting in 2025.
The FDA recently granted accelerated approval for Fabhalta to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, and development is ongoing in multiple complement-mediated diseases.
Last month, Novartis raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42115127/novartis-confident-in-growth-as-it-elevates-midterm-sales-forecast-ceo-narasimhan-highlights-robust-pipeline-supporting-long-term-strategy" rel="noreferrer noopener">for 2023-2028</a>.
The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.
Earlier this week, PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) signed an exclusive global license and collaboration agreement with&nbsp;Novartis for its PTC518 Huntington&#8217;s disease program, which&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42272846/ptc-therapeutics-inks-licensing-pact-with-novartis-worth-3-billion-for-huntingtons-program" rel="noreferrer noopener">includes related molecules</a>.
Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.
<h2 class="wp-block-heading">Is Novartis A Good Stock To Buy?</h2>
Wall Street analysts view Novartis on the whole as a Neutral, given the history of coverage over the past three months. Graham Perry from B of A Securities in Novartis is the most bearish, expecting a 3.7% fall in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Novartis fell 12.4%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 8.84% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
Price Action: At the last check on Friday, NVS stock was up 0.18% to $102.34.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42359798/asia-markets-mixed-europe-advances-oil-slides-while-gold-and-dollar-strengthen-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">China And Europe Markets Advance, Gold And Dollar Tick Higher &#8211; Global Markets Today While US Slept</a></li>
</ul>
Photo by Taljat David via Shutterstock

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Press Releases

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Investing: How PRVs Can Unlock Major Opportunities

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

Comments

PTC Therapeutics

PTC Therapeutics (PTCT) Options

PTC Therapeutics (NASDAQ:PTCT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL